- ￥849 - 5300
- MedChemExpress(MCE)
- 美国
- HY-U00418
- 2025年12月05日
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
Powder: -20°C, 3 years; 4°C, 2 years.In solvent: -80°C, 6 months; -20°C, 1 month.
- 库存：
货期：1-2天
- 供应商：
MedChemExpress LLC
- CAS号：
1698055-85-4
- 规格：
10 mM * 1 mL/1 mg/5 mg/10 mg/25 mg
| 规格： | 10 mM * 1 mL | 产品价格： | ￥1990.0 |
|---|---|---|---|
| 规格： | 1 mg | 产品价格： | ￥849.0 |
| 规格： | 5 mg | 产品价格： | ￥2100.0 |
| 规格： | 10 mg | 产品价格： | ￥3360.0 |
| 规格： | 25 mg | 产品价格： | ￥5300.0 |
MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。
ARS-1620
CAS No. : 1698055-85-4
MCE 国际站：ARS-1620
产品活性：ARS-1620 是一种阻转异构且有选择性的 KRASG12C 抑制剂，具有理想的药代动力学。
研究领域：GPCR/G Protein
作用靶点：Ras
In Vitro: ARS-1620 is an atropisomeric selective KRASG12C inhibitor with desirable pharmacokinetics. ARS-1620 exhibits complete growth suppression of p.G12C cell lines (IC50=150 nM) with relatively benign effects on control cell lines. It is found that ARS-1620 significantly reduces expression of the gene set in p.G12C mutant cells in a time-dependent manner but not in the p.G12S mutant cells. Following a 5-day treatment period, only a minority of G12C mutant cell lines are sensitive to ARS-1620 under monolayer culture conditions, whereas in 3D-spheroid conditions, ARS-1620 elicits a robust response (p=0.0140).
In Vivo: Following a single oral dose or 5 consecutive daily doses, ARS-1620 yields average peak tumor concentrations of 1.5 μM (50 mg/kg) and 5.5 μM (200 mg/kg), respectively, that enables significant KRASG12C target occupancy (>=70% G12C-TE at 200 mg/kg) for >24 hr. In MIAPaCa2 xenografts (p.G12C), ARS-1620 significantly inhibits tumor growth (p<0.001) in a dose-dependent manner with marked regression at a dose of 200 mg/kg, given once daily. Across all tumor models employed, ARS-1620 is well tolerated over the entire 3-week treatment period. Moreover, there are no observed clinical signs or toxicity of ARS-1620 in CD-1 mice even at oral doses up to 1,000 mg/kg administered daily over a 7-day period.
相关产品：Bioactive Compound Library Plus | GPCR/G Protein Compound Library | Kinase Inhibitor Library | Anti-Cancer Compound Library | Ferroptosis Compound Library | Glutamine Metabolism Compound Library | Anti-Lung Cancer Compound Library | Anti-Pancreatic Cancer Compound Library | Anti-Blood Cancer Compound Library | Angiogenesis-Related Compound Library | Targeted Diversity Library | Anti-Liver Cancer Compound Library | Anti-Colorectal Cancer Compound Library | Membrane Protein-targeted Compound Library | Membrane Receptor-targeted Compound Library | Highly Selective Inhibitors Library | Sotorasib | MRTX1133 | Adagrasib | BI-2852 | BI-3406 | Ketoconazole | NSC 23766 trihydrochloride | BI-2865 | ML141 | BAY-293 | CID-1067700 | Rhosin hydrochloride | Lonafarnib | EHT 1864 | GGTI298 Trifluoroacetate | MBQ-167 | MRTX0902 | Opnurasib | Divarasib | CCG-1423 | CASIN | Salirasib | EHop-016 | RMC-6291 | ML-098 | MRTX-1257 | FTI-277 hydrochloride | Pan-RAS-IN-1
热门产品线：重组蛋白 | 化合物库 | 天然产物 | 荧光染料 | PROTAC | 同位素标记物
Trending products：Recombinant Proteins | Bioactive Screening Libraries | Natural Products | Dye Reagents | PROTAC | Isotope-Labeled Compounds
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验Replication timing using transient hemimethylation
, and the transformant exhibiting the highest level of DpnI cleavage was selected (RM14-3a Meth5 strain). Protocol for methylation timing 1. Grow ~330 ml of RM14-3a expressing dam methylase (RM14-3a Meth5) to an OD660 of about 0.3 (3.85 x 106 cells/ml) at 23o C
【摘要】 目的 研究用高效液相色谱测定女贞子中齐墩果酸含量的方法,并与薄层扫描色谱法比较。方法色谱柱为kromasil C18（5 μm，250 mm×4.6 mm）；柱温30℃； 流动相甲醇-水（85∶15）；流速0.7 ml・min-1；检测波长为204 nm。结果齐墩果酸在0.645 6～4.304 μg范围内线性关系良好，r=0.999 9（n=5）,平均回收率为101.8%，RSD=0.75%。结论高效液相色谱法比薄层扫描色谱法更灵敏、简便、准确，精密度好。
科研民工救星：JAMA子刊发现它既能祛痘，还能治脱发，今日已被FDA批准上市
痤疮是世界上第八大流行的疾病，影响着全球超过 6.4 亿人。痤疮的发生通常与青春期的激素变化是一致的，并且影响着大约 85% 的青少年和 12 到 25 岁的年轻人。图片来源：站酷海洛 Plus近年来，治疗痤疮的新疗法创新很少，自 1982 年异维A酸（isotretinoin）以来，已经近 40 年没有新的作用机制的药物被美国食品和药物管理局（FDA）引入并批准。当地时间 2020 年 8 月 27 日，Cassiopea 公司宣布，FDA 批准了 Winlevi®（Clascoterone
技术资料暂无技术资料 索取技术资料
